HIV-associated Lipodystrophy Market Growth, Price and Forecast HIV-associated Lipodystrophy Market - Global Indus

HIV-associated Lipodystrophy Market - Global Industry
Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025
Changes in body fat concentration, affecting people with HIV, is known as HIV-associated
lipodystrophy. The exact causes of this condition is currently unknown, but research suggests that this
disorder can occur either due to HIV infection or as a consequence of side effects associated with
drugs used in HIV infection treatment, such as Nucleoside/Nucleotide Reverse Transcriptase
Inhibitors (NRTIs), Protease Inhibitors (PIs), etc. The lipodystrophy condition is characterized by
metabolic abnormalities, including insulin resistance, and dyslipidemia. The HIV-associated
lipodystrophy groups together different clinical conditions, which are lipoatrophy and lipoaccumulation.
Lipoatrophy is associated with subcutaneous fat loss, whereas lipoaccumulation is the increase in
visceral fat. In certain cases, HIV-associated lipodystrophy may occur as a combination of these two
conditions; thus, its treatment and prevalence measurement are difficult.
Request for brochure of this report -
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22925
The global HIV-associated lipodystrophy market is witnessing unprecedented dynamics. Several
research studies are directed toward finding out the link between the two mechanisms of lipodystrophy
in such a way that a single mechanism will can occur for redistribution of fat. Improving healthcare
infrastructure and increasing incidence rates of HIV/AIDS patients globally are expected to drive the
growth of the global HIV-associated lipodystrophy market. However, lower adoption of therapeutic
treatment and demand for constant nutritional supply from patients is anticipated to restrain the growth
of the global HIV-associated lipodystrophy market.
The global HIV-associated lipodystrophy market has been segmented based on lipodystrophy type,
therapeutic class, and distribution channels. On the basis of lipodystrophy type, the market has been
classified into lipoatrophy and lipoaccumulation. In terms of therapeutic class, the market is divided
into anabolism modulators, insulin resistance modulators, mitochondrial antioxidants (L-carnitine), and
other miscellaneous metabolic agents. Anabolism modulators are further bifurcated into growth
hormones and anabolic steroids. Insulin resistance modulators can be sub-segmented into
metformins, thiazolidinediones, and others. Growth hormones are widely used for the treatment of
HIV-associated lipodystrophy due to their efficacy. Based on distribution channels, the global HIV-
associated lipodystrophy market is categorized into hospital pharmacy stores, retail pharmacy stores,
and online pharmacies. Hospital pharmacy stores are expected to account for higher market share
due to their ease of connectivity, and trend of utilization of newly advanced products among end-users
including physicians and patients.
There is a lack of evidence-based strategies for the treatment of HIV-associated lipodystrophy. The
treatment switch between the two lipodystrophy conditions, along with HIV drugs that possess lower
mitochondrial toxicity, is an emerging trend in the global HIV-associated lipodystrophy market. There
is a large patient pool in emerging countries, where lower drug affordability is a major challenge for
market penetration of HIV-associated lipodystrophy therapeutics. Thus, the introduction of affordable
drugs by local manufacturers serves as a major opportunity in the global HIV-associated lipodystrophy